Biorce announced the closing of a $52.5 million (€44.3 million) funding round to accelerate development of its artificial intelligence software for clinical trials and drive international expansion, with a strong focus on the United States. The round was led by DST Global, with participation from existing investors Norrsken VC, YZR Capital, and Mustard Seed Maze, alongside Endeavor Catalyst and a group of technology founders and executives.
Founded in Barcelona in 2024 by Pedro Coelho and co-founders Clara Bernardes, José Faria, and Diogo Pisoeiro, Biorce is developing Aika, an AI platform designed to streamline clinical trial design and execution. The company plans to expand its team, enhance Aika’s capabilities, open an R&D center in Austin, and scale operations across Europe and the U.S.
